Anti-FGF23 monoclonal antibody
Burosumab
Brand names: Crysvita
Adult dose
Dose: Adults: 1mg/kg SC q4w; Children: per body weight per SmPC q2w
Route: Subcutaneous
Frequency: q4w (adult) / q2w (child)
Clinical pearls
- NICE HST8 (paediatric XLH); NICE TA791 (adult)
- X-linked hypophosphataemia — specialist metabolic / endocrine centres
- Royal Osteoporosis Society / BPNA guidance
Contraindications
- Concurrent oral phosphate / vitamin D analogues
- Severe renal impairment
- Hyperphosphataemia
- Hypersensitivity
Side effects
- Injection-site reactions
- Headache
- Hypersensitivity
- Restless legs
- Hyperphosphataemia
- Ectopic mineralisation
Interactions
- Oral phosphate / active vitamin D analogues (avoid)
Monitoring
- Phosphate
- 1,25(OH)2D
- Renal function
- Skeletal radiology
- Growth
Reference: BNF; NICE HST8; NICE TA791; ROS; SmPC; https://bnf.nice.org.uk/drugs/burosumab/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Revised Original International Autoimmune Hepatitis Score (IAIHG) · Autoimmune Liver Disease
- Ho Index for Predicting Response to Medical Therapy in IBD · Inflammatory Bowel Disease
- Rh(D) Immune Globulin Dosage for Maternal-Fetal Haemorrhage · Haematology in Pregnancy
- AREDS Classification of Age-related Macular Degeneration · Macular Degeneration
- Diabetic Macular Oedema (DMO) Classification · Diabetic Retinopathy
- Retinopathy of Prematurity — International Classification (ICROP3) · Paediatric Retina
Pathways
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016